Sugi Predict

Sugi Predict / Compounds / SCHEMBL2184302

SCHEMBL2184302

SCHEMBL2184302

COc1nn(C)cc1[N+](=O)[O-]

nearest known ligand 0.44

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
▸ MAPT P10636 3/20 0.44
▸ ALDH1A1 P00352 3/20 0.44
▸ POLB P06746 1/20 0.44
▸ L3MBTL1 Q9Y468 1/20 0.42
▸ LMNA P02545 3/20 0.41
▸ NPSR1 Q6W5P4 2/20 0.41
▸ CYP2C9 P11712 1/20 0.41
▸ HTT P42858 2/20 0.40
▸ HPGD P15428 1/20 0.40
▸ TDP1 Q9NUW8 1/20 0.40
▸ MERTK Q12866 1/20 0.40
▸ SMN1; SMN2 Q16637 1/20 0.39
▸ MEN1 O00255 1/20 0.38
▸ MITF O75030 1/20 0.38
▸ S1PR4 O95977 1/20 0.38
▸ S1PR1 P21453 1/20 0.38
▸ NTSR1 P30989 1/20 0.38
▸ KMT2A Q03164 1/20 0.38
▸ HTR7 P34969 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL22518573 0.80 CYP2C9 (0.49) MAPTALDH1A1POLBL3MBTL1LMNA
SCHEMBL18418864 0.80 L3MBTL1 (0.42) MAPTALDH1A1POLBL3MBTL1LMNA
SCHEMBL24792528 0.80 ALDH1A1 (0.41) MAPTALDH1A1POLBL3MBTL1LMNA
SCHEMBL31714353 0.79 CYP2C9 (0.46) MAPTALDH1A1POLBL3MBTL1LMNA
SCHEMBL27895453 0.79 L3MBTL1 (0.44) MAPTALDH1A1POLBL3MBTL1LMNA
SCHEMBL30380703 0.79 SMN1; SMN2 (0.47) MAPTALDH1A1POLBL3MBTL1LMNA
SCHEMBL31714482 0.78 MAPT (0.42) MAPTALDH1A1POLBLMNANPSR1
SCHEMBL17837151 0.78 CYP2C9 (0.42) MAPTALDH1A1POLBL3MBTL1LMNA
SCHEMBL28412873 0.78 L3MBTL1 (0.43) MAPTALDH1A1POLBL3MBTL1LMNA
SCHEMBL31713068 0.77 SMN1; SMN2 (0.43) MAPTALDH1A1POLBL3MBTL1LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 29 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12630539-B2 Amide compound, pharmaceutical composition and use thereof ARTIVILA (SHENZHEN) INNOVATION CENTER, LTD. (CN) 2026-05-19 — — US disclosed
EP-4253375-B1 AMIDE COMPOUND, PHARMACEUTICAL COMPOSITION AND USE THEREOF ARTIVILA SHENZHEN INNOVATION CENTER LTD (CN) 2026-01-07 — — EP disclosed
WO-2025092989-A1 SUBSTITUTED QUINAZOLINE COMPOUND, PREPARATION METHOD THEREFOR, PHARMACEUTICAL COMBINATION THEREOF, AND USE THEREOF 泰州红云制药有限公司 2025-05-08 — — WO disclosed
US-12234232-B2 Aromatic heterocyclic compound with kinase inhibitory activity SHANGHAI ENNOVABIO PHARMACEUTICALS CO., LTD. (CN) 2025-02-25 — — US disclosed
EP-4341248-A1 USE OF AN N-FUNCTIONALIZED ALKOXY PYRAZOLE COMPOUND AS NITRIFICATION INHIBITOR BASF SE (DE) 2024-03-27 — — EP disclosed
CN-112823159-B Aromatic heterocyclic compounds with kinase inhibitory activity 上海轶诺药业有限公司 2024-03-01 — — CN disclosed
CN-114269736-B Amide compound, pharmaceutical composition and application thereof 科辉智药(深圳)新药研究中心有限公司 2024-02-02 — — CN disclosed
US-20230416237-A1 AMIDE COMPOUND, PHARMACEUTICAL COMPOSITION AND USE THEREOF ARTIVILA (SHENZHEN) INNOVATION CENTER, LTD. (CN) 2023-12-28 — — US disclosed
EP-4253375-A1 AMIDE COMPOUND, PHARMACEUTICAL COMPOSITION AND USE THEREOF Artivila (ShenZhen) Innovation Center, Ltd. (CN) 2023-10-04 — — EP disclosed
EP-4253375-A1 AMIDE COMPOUND, PHARMACEUTICAL COMPOSITION AND USE THEREOF Artivila (ShenZhen) Innovation Center, Ltd. (CN) 2023-10-04 — — EP disclosed
EP-3854793-A1 AROMATIC HETEROCYCLIC COMPOUND WITH KINASE INHIBITORY ACTIVITY Shanghai Ennovabio Pharmaceuticals Co., Ltd. (CN) 2021-07-28 — — EP disclosed
WO-2020156283-A1 ALKYNYLPYRIMIDINE OR ALKYNYLPYRIDINE COMPOUND, AND COMPOSITION AND APPLICATION THEREOF 北京赛特明强医药科技有限公司 2020-08-06 — — WO disclosed
CN-111484482-A Alkynyl pyrimidine or alkynyl pyridine compound, and composition and application thereof 北京赛特明强医药科技有限公司 2020-08-04 — — CN disclosed
WO-2020057669-A1 AROMATIC HETEROCYCLIC COMPOUND WITH KINASE INHIBITORY ACTIVITY 上海轶诺药业有限公司 2020-03-26 — — WO disclosed
WO-2020057669-A1 AROMATIC HETEROCYCLIC COMPOUND WITH KINASE INHIBITORY ACTIVITY 上海轶诺药业有限公司 2020-03-26 — — WO disclosed
CN-102124000-B Pyridine compounds ASTRAZENECA AB 2014-09-17 — — CN disclosed
EP-2303861-B1 PYRIDINE COMPOUNDS ASTRAZENECA AB (SE) 2014-04-23 — — EP disclosed
US-8569298-B2 Pyridine compounds ASTRAZENECA AB (SE) 2013-10-29 — — US disclosed
CN-102124000-A Pyridine compounds ASTRAZENECA AB 2011-07-13 — — CN disclosed
US-20110166139-A1 PYRIDINE COMPOUNDS ASTRAZENECA AB (SE) 2011-07-07 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12630539-B2 Amide compound, pharmaceutical composition and use thereof JAK2, JAK1, JAK3 MAPT 4013/4885ALDH1A1 3620/4885POLB 3643/4885
US-20230416237-A1 AMIDE COMPOUND, PHARMACEUTICAL COMPOSITION AND USE THEREOF JAK1, JAK2, JAK3 MAPT 2846/4885ALDH1A1 2156/4885POLB 3374/4885
US-12234232-B2 Aromatic heterocyclic compound with kinase inhibitory activity JAK1, JAK2, JAK3 MAPT 3205/4885ALDH1A1 1724/4885POLB 3170/4885
US-20110166139-A1 PYRIDINE COMPOUNDS PTK2, PTK2B, PFKP MAPT 967/4885ALDH1A1 2505/4885POLB 3557/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.